The study is a single-center, randomized, double-blind, placebo-controlled study in middle-aged to elderly adults with excessive body weight. The study includes an 8-week intervention period followed by a 2-week follow-up period. The study will evaluate the effect of a synbiotic consisting of two probiotic strains and a prebiotic.
The aim is to investigate the effect of the synbiotic on modulating the gut microbiota and improving markers of gastrointestinal permeability and integrity and gastrointestinal discomfort.
Be able to give informed consent.
Be between 50 to 70 years of age (inclusive).
BMI ranging from 25.0 and 35.0 kg/m²
Willing to maintain current level of physical activity and diet during the participation in the study.
Has a history of drug and/or alcohol abuse.
Has food allergies, or other issues with foods, that would preclude intake of the study products.
Smoking, chewable tobacco and/or vaping and/or use of other nicotine products.
diagnosis of GI disease (e.g. gastric or duodenal ulcers, inflammatory bowel disease, colon cancer) or irritable bowel syndrome (IBS)